NO331083B1 - Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati - Google Patents

Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati

Info

Publication number
NO331083B1
NO331083B1 NO20033228A NO20033228A NO331083B1 NO 331083 B1 NO331083 B1 NO 331083B1 NO 20033228 A NO20033228 A NO 20033228A NO 20033228 A NO20033228 A NO 20033228A NO 331083 B1 NO331083 B1 NO 331083B1
Authority
NO
Norway
Prior art keywords
inhibitor
expression vector
cardiomyopathy
inducing
enhancing
Prior art date
Application number
NO20033228A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033228D0 (no
NO20033228L (no
Inventor
Charles Dinarello
Yolande Chvatchko
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20033228D0 publication Critical patent/NO20033228D0/no
Publication of NO20033228L publication Critical patent/NO20033228L/no
Publication of NO331083B1 publication Critical patent/NO331083B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20033228A 2001-01-29 2003-07-16 Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati NO331083B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (3)

Publication Number Publication Date
NO20033228D0 NO20033228D0 (no) 2003-07-16
NO20033228L NO20033228L (no) 2003-09-26
NO331083B1 true NO331083B1 (no) 2011-10-03

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033228A NO331083B1 (no) 2001-01-29 2003-07-16 Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati

Country Status (31)

Country Link
US (1) US20040234523A1 (https=)
EP (1) EP1355668B1 (https=)
JP (2) JP4860897B2 (https=)
KR (1) KR100857376B1 (https=)
CN (1) CN1326562C (https=)
AR (1) AR032422A1 (https=)
AT (1) ATE380558T1 (https=)
BG (1) BG66483B1 (https=)
BR (1) BR0206819A (https=)
CA (1) CA2435466C (https=)
CY (1) CY1107203T1 (https=)
CZ (1) CZ305653B6 (https=)
DE (1) DE60224004T2 (https=)
DK (1) DK1355668T3 (https=)
EA (2) EA006767B1 (https=)
EE (1) EE05534B1 (https=)
ES (1) ES2295332T3 (https=)
HR (1) HRP20030609A2 (https=)
HU (1) HU229164B1 (https=)
IL (2) IL157024A0 (https=)
ME (1) ME00549B (https=)
MX (1) MXPA03006776A (https=)
NO (1) NO331083B1 (https=)
PL (1) PL213568B1 (https=)
PT (1) PT1355668E (https=)
RS (1) RS51125B (https=)
SI (1) SI1355668T1 (https=)
SK (1) SK287620B6 (https=)
UA (1) UA80676C2 (https=)
WO (1) WO2002060479A1 (https=)
ZA (1) ZA200305439B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (https=) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
CA2424983A1 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン18阻害剤を有効成分とする疾患の予防又は治療剤
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
JP5968590B2 (ja) * 2007-11-05 2016-08-10 ケーシーアイ ライセンシング インコーポレイテッド 創面切除のための組織の同定
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
CN115925928A (zh) * 2013-09-05 2023-04-07 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
WO2018013509A1 (en) * 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
EP0929311B8 (en) * 1996-09-12 2006-02-01 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
EP0942925B1 (en) * 1996-12-06 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
JP2002539183A (ja) * 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換2−アミノベンズアミドカスパーゼインヒビターおよびその使用
CN1176941C (zh) * 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
WO2001003719A2 (en) * 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
TWI335336B (https=) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
EE05056B1 (et) * 2000-05-05 2008-08-15 Applied Research Systems Ars Holding N.V. IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
DE60224004D1 (de) 2008-01-24
BG108128A (bg) 2004-11-30
CZ305653B6 (cs) 2016-01-27
EA200300844A1 (ru) 2003-12-25
HU229164B1 (en) 2013-09-30
UA80676C2 (en) 2007-10-25
YU57803A (sh) 2006-05-25
CN1326562C (zh) 2007-07-18
EA200501549A1 (ru) 2006-04-28
SK10892003A3 (sk) 2004-02-03
EA006767B1 (ru) 2006-04-28
HUP0303306A3 (en) 2005-12-28
CY1107203T1 (el) 2012-11-21
EP1355668B1 (en) 2007-12-12
EE200300328A (et) 2003-10-15
BR0206819A (pt) 2004-02-03
EE05534B1 (et) 2012-04-16
JP2004522748A (ja) 2004-07-29
KR100857376B1 (ko) 2008-09-05
HK1062810A1 (en) 2004-11-26
BG66483B1 (bg) 2015-03-31
IL157024A0 (en) 2004-02-08
CZ20032335A3 (en) 2004-07-14
ME00549B (me) 2011-10-10
ES2295332T3 (es) 2008-04-16
JP2009102354A (ja) 2009-05-14
JP4860897B2 (ja) 2012-01-25
PL366802A1 (en) 2005-02-07
SI1355668T1 (sl) 2008-06-30
NO20033228D0 (no) 2003-07-16
HRP20030609A2 (en) 2005-06-30
EA010180B1 (ru) 2008-06-30
NO20033228L (no) 2003-09-26
CA2435466C (en) 2012-04-03
KR20030070143A (ko) 2003-08-27
PL213568B1 (pl) 2013-03-29
RS51125B (sr) 2010-10-31
PT1355668E (pt) 2008-01-04
CN1499982A (zh) 2004-05-26
ATE380558T1 (de) 2007-12-15
EP1355668A1 (en) 2003-10-29
IL157024A (en) 2014-02-27
SK287620B6 (sk) 2011-04-05
ZA200305439B (en) 2004-07-15
DE60224004T2 (de) 2009-07-23
MXPA03006776A (es) 2003-10-24
CA2435466A1 (en) 2002-08-08
WO2002060479A1 (en) 2002-08-08
DK1355668T3 (da) 2008-05-05
HUP0303306A2 (hu) 2004-01-28
AR032422A1 (es) 2003-11-05
US20040234523A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20062508L (no) Administrering av levodopa og karbidopa
DK1590047T3 (da) Sammensætning, som omfatter lactobacillus eller bifidobacterium, og anvendelse deraf
DK1373191T3 (da) Acylerede indanylaminer og deres anvendelse som lægemidler
NO20033566D0 (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
DK2336167T3 (da) MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
IS2485B (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
NO331083B1 (no) Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
DK1353912T3 (da) 2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
NO20053588D0 (no) Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
DK1372665T3 (da) Hormonerstatningsbehandling og administration

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired